VALENCIA, SPAIN / ACCESSWIRE / Ocotber 27, 2014 / Zenosense, Inc. (OTCQB: ZENO) ("Zenosense", the "Company"), a healthcare technology company primarily focused on developing and marketing devices to detect the MRSA “Super-Bug” and to detect signs of lung cancer in exhaled breath, is pleased to announce considerable progress made in the development of its MRSA/SA detector. The prototype device successfully achieved a sensibility detection rate greater than 95% on cultured headspace in a series of tests over a two week period in a clinical setting.
General device technology development, to detect the Methicillin-resistant Staphylococcus aureus "Super-Bug" ("MRSA"), non-resistant "Staph" ("SA"), is also proceeding in line with Company expectations.
Electronic improvements have resulted in printed circuit board prototyping that includes;
- Integration of a powerful solid state processor;
- Integration of a suitable, low power, piezo electric sampling pump;
- Capability to run up to four sensors of different technologies working in parallel on a tens of milliseconds sampling frequency, to include measuring and cleaning time; and
- Very low power consumption enabling an extended operating time on battery power to cover at least one normal working shift when operating continuously.
Encapsulation design and prototyping has produced a handy and easy-to-use commercial package to house the circuitry and hardware elements.
A Volatile Organic Compound ("VOC") capturing system and protocol to enable the prototyped device to sample cultured headspace has been developed. This includes an air injection system to enable the device to sample a negative vacuum, a suction process, data download and a cleaning cycle.
Next steps in development will include Quartz Crystal Microbalance sensor testing, sensitivity testing against VOC biomarkers, assessment of accuracy and repeatability, and a review of sensitivity to temperature, humidity and gas interference factors.
About Zenosense, Inc.
Zenosense, Inc. is a detection device development company based in Valencia, Spain. Its mission is to develop effective medical devices targeting the early detection of both deadly bacteria and certain cancers in the exhaled breath of patients and market and sell these products to hospitals and primary healthcare facilities. Two devices are currently under development; a device intended to detect the Methicillin-resistant Staphylococcus aureus "Super-Bug" (MRSA); and a device intended to detect Lung Cancer. Using a common Electronic Nose technology platform, the devices analyze Volatile Organic Compounds (VOCs) which are present in the exhaled breath of patients, scanning for certain biomarkers which can indicate the presence of infection/illness.
Find out more at www.zenosense.net
Forward-Looking Statements
Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties. Forward-looking statements can often be identified by words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company. Readers are cautioned not to place undue reliance on such forward-looking statements. Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 filed on filed on March 26, 2014, and in Company reports filed subsequently thereto. Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Statements concerning the development of both the MRSA device and the lung cancer device have been made based on information obtained from Zenon Biosystem, which the Company believes to be accurate, but have not been independently verified.
CONTACT:
Zenosense, Inc.
Email: [email protected]
Tel: +34 960 454 202
Web: www.zenosense.net
SOURCE: Zenosense, Inc.